Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability

Abstract

In our opinion, replacing liver microsome and hepatocyte assays with S9 assay for high throughput metabolic screening purposes provides the combined benefit of comprehensive and high quality data at a reasonable expense for drug discovery programs.